IGRA/MAT-1: Evaluation of a CD4/CD8+ Interferon Gamma Release Assay for Monitoring Anti-Tuberculosis Treatment
Study Details
Study Description
Brief Summary
Evaluate the possibility of using an IGRA (Interferon-γ Release Assay) test for monitoring the response to anti-tuberculosis therapy by studying the correlation between the variation in the Interferon-gamma (IFN-γ) response to the QFT-Plus test in the two tubes containing antigens and the gold standard for monitoring TB therapy (culture conversion) in patients with slide positive/culture positive and slide negative/culture positive PTB.
Evaluate the level of agreement between the results of the new QFT Access test and the results of the QFT plus and culture in patients diagnosed with active tuberculosis. To evaluate the level of agreement between QFT Access test results and QFT Plus results in healthy controls and contacts.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Control Group (healthy subject)
|
Diagnostic Test: Interferon gamma release assay (IGRA)
in vitro test
|
| Subject with Pulmonary Tuberculosis (PTB)
|
Diagnostic Test: Interferon gamma release assay (IGRA)
in vitro test
|
Outcome Measures
Primary Outcome Measures
- Evaluation of a CD4/CD8+ Interferon Gamma Release Assay for monitoring anti-Tuberculosis treatment [1. At time of diagnosis (t0) 2. 30+ 4 days after anti-TB treatment initiation (t1) 3. 2 months after anti-TB treatment initiation (t2) 4. At the end of the anti-TB therapy (6 to 9 months) (t3)]
Define the degree of correlation between changes in IFN-γ response in the first antigen tube (TB1) and the newly added antigen tube (TB2) and the reference stand-ard of treatment response (culture conversion) in smear-positive and smear-negative/culture-positive pulmonary TB cases
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Clinical symptoms consistent with a high probability of having PULMONARY TB disease (probable case), such that they are receiving or are likely to receive ther-apy for active PTB (therapy must not have been initiated for more than 72 hours before recruitment into the study).
-
Positive sputum smear for AAR
-
Positive culture for mycobacterium tuberculosis (confirmed PTB case).
-
Positive nucleic acid amplification (NAA) test for mycobacterium tuberculosis.
Exclusion Criteria:
-
Taken therapy for active tuberculosis or latent TB infection for more than 72 hours.
-
Culture confirmation of M. tuberculosis not obtained.
-
Age less than 18 years.
-
Immunosuppression: HIV-infection, solid organ transplantation, stem cell transplantation, rheumatoid arthritis.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | IRCCS San Raffaele Scientific Institute | Milano | Italy | 20132 |
Sponsors and Collaborators
- Paola Mantegani
Investigators
- Principal Investigator: Daniela M Cirillo, MD,PhD, IRCCS San Raffaele Scientific Institute Via Olgettina 60 20132 Milan Italy
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IGRA/MAT-1